DrugMay 14, 2025
Apollo Care FentaNYL 500mcg (2mcg/mL) and Ropivacaine HCl 250mg (0.1%) added to 250 mL, 0.9% recall — FDA D-0409-2025
Lack of Assurance of Sterility
Class IIFDA: OngoingApollo Care, LLC
Monthly breakdown
2025 recalls by month
Select a month to review the recall records reported during that period.
December 2025101 records · 3 categoriesNovember 202596 records · 3 categoriesOctober 2025133 records · 3 categoriesSeptember 2025116 records · 3 categoriesAugust 202582 records · 3 categoriesJuly 202537 records · 2 categoriesJune 202525 records · 2 categoriesMay 202553 records · 2 categoriesApril 202542 records · 2 categoriesMarch 202532 records · 2 categoriesFebruary 202527 records · 2 categoriesJanuary 202526 records · 2 categories
2025 recalls — page 27
Records are ordered by the best available source date.
DrugMay 14, 2025
BSO TESTOSTERONE PELLET 200 mg BLUNT, 1 Pellet for Subcutaneous Use, This is a Compounded recall — FDA D-0416-2025
Presence of Particulate Matter: Glass particles were found in pellet vials.
Class IIFDA: OngoingBSO LLC
DrugMay 14, 2025
BRS Analytical Services Carboxymethylcellulose Sodium Ophthalmic Gel 1% recall — FDA D-0405-2025
cGMP deviations and lack of assurance of sterility.
Class IIFDA: OngoingBRS Analytical Services, LLC
DrugMay 14, 2025
BSO TESTOSTERONE PELLET 100 mg (with Cholesterol </=4%), 1 Pellet for Subcutaneous Use, This recall — FDA D-0412-2025
Presence of Particulate Matter: Glass particles were found in pellet vials.
Class IIFDA: OngoingBSO LLC
DrugMay 14, 2025
Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL) recall — FDA D-0402-2025
Presence of Particulate Matter
Class IFDA: OngoingAmneal Pharmaceuticals, LLC
DrugMay 14, 2025
Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 10mL bottles recall — FDA D-0403-2025
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
Class IIFDA: OngoingFDC Limited
DrugMay 14, 2025
Artificial Tears Ophthalmic Solution, Dextran 70.01%/Glycerin 0.2%/Hypromellose 0.3% recall — FDA D-0404-2025
cGMP deviations and lack of assurance of sterility.
Class IIFDA: OngoingBRS Analytical Services, LLC
VehicleMay 9, 2025
Ford back over prevention software recall — NHTSA campaign 25V315000
Ford Motor Company (Ford) is recalling certain 2021-2024 Bronco, F-150, 2021-2024 Edge, 2022-2025 Escape, F-250, F-350, F-450, F-550, F-600, 2022-2024 Expedition, 2022-2025 Transit,…
back over prevention softwareFord Motor Company
VehicleMay 9, 2025
F-150 steering recall — NHTSA campaign 25V309000
Ford Motor Company (Ford) is recalling certain 2025 F-150 vehicles. The lower intermediate shaft fasteners may be improperly attached to the steering gear, allowing the shaft to come loose…
steeringFord Motor Company
VehicleMay 8, 2025
Chrysler gear position indication (prndl) recall — NHTSA campaign 25V297000
Chrysler (FCA US, LLC) is recalling certain Ram 2500 and Ram 3500 vehicles equipped with a 3.5" cluster and column shifter. A software error may cause the gear selection display to be…
gear position indication (prndl)Chrysler (FCA US, LLC)
VehicleMay 8, 2025
Ram 1500 air bags recall — NHTSA campaign 25V298000
Chrysler (FCA US, LLC) is recalling certain 2019-2024 Ram 1500 vehicles. The driver's side air bag may not be connected properly, which can cause the air bag not to deploy as intended. As…
air bagsChrysler (FCA US, LLC)
DrugMay 7, 2025
Mckesson Medical-Surgical Inc. Corporate Office Medroxyprogesterone Acetate Injectable recall — FDA D-0400-2025
Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and…
Class IIFDA: OngoingMckesson Medical-Surgical Inc. Corporate Office
DrugMay 7, 2025
niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial recall — FDA D-0399-2025
Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.
Class IIFDA: OngoingAmerican Regent, Inc.
DrugMay 7, 2025
Infuvite Adult, multiple vitamins injection, Baxter, Five of Vial 1 (5 mL) and Five of Vial recall — FDA D-0401-2025
Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and…
Class IIFDA: OngoingMckesson Medical-Surgical Inc. Corporate Office
DrugMay 7, 2025
Nubratori Dexonto 0.4% recall — FDA D-0392-2025
Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto…
Class IIFDA: OngoingNubratori, Inc
DrugMay 7, 2025
Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container recall — FDA D-0389-2025
Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.
Class IIFDA: OngoingEugia US LLC
DrugMay 7, 2025
niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Single Dose Vial recall — FDA D-0398-2025
Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.
Class IIFDA: OngoingAmerican Regent, Inc.
DrugMay 7, 2025
Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container recall — FDA D-0390-2025
Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.
Class IIFDA: OngoingEugia US LLC
DrugMay 7, 2025
Cardinal Health Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens recall — FDA D-0393-2025
Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products labeled storage conditions due to a shipping error involving a Cardinal Health distribution…
Class IIFDA: OngoingCardinal Health Inc.
DrugApr 30, 2025
clomiPRAMINE hydrochloride Capsules USP, 25 mg, 100-count bottle recall — FDA D-0377-2025
Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability…
Class IIFDA: TerminatedLupin Pharmaceuticals Inc.
DrugApr 30, 2025
Denver Solutions, LLC DBA Leiters Health dexmedeTOMIDine HCl PF, in 0.9% Sodium Chloride, 20 recall — FDA D-0371-2025
Lack of Assurance of Sterility: Leaking/damaged syringes.
Class IIFDA: OngoingDenver Solutions, LLC DBA Leiters Health
DrugApr 30, 2025
OurPharma HYDROmorphone Hydrochloride 50mg/50mL (1mg/mL) recall — FDA D-0385-2025
Superpotent Drug: Assay/potency result for hydromorphone HCl in the compounded stability lot was higher than specification..
Class IIIFDA: TerminatedOurPharma LLC
DrugApr 30, 2025
Haloperidol Decanoate Injection, 50mg/mL* , 1 mL Single-Dose Vial recall — FDA D-0367-2025
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
Class IIFDA: OngoingAmerisource Health Services LLC
DrugApr 30, 2025
Haloperidol Decanoate Injection, 100mg/mL*, 5 x 1 mL Single-Dose Vials recall — FDA D-0369-2025
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
Class IIFDA: OngoingAmerisource Health Services LLC
About the 2025 recall archive
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.